Neuroprotective effect of 5-HT3 receptor antagonist on ischemia-induced decrease in CA1 field potential in rat hippocampal slices

Yoshifumi Kagami-ishi, Shigenobu Shibata, Shigenori Watanabe

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The effect of 5-HT3 receptor agonists and antagonists on the hypoxia/hypoglycemia (ischemia)-induced decrease in CA1 field potential elicited by stimulation of Schaffer collaterals was investigated using rat hippocampal slices. Treatment with the 5-HT3 receptor agonist, 2-methyl-5-HT (1-10 μM), exaceebated the ischemia-induced decreased in CA1 field potential, whereas treatment with the 5-HT3 receptor antagonist. Y-25130 (0.1-100 μM), or the 5-HT2 receptor antagonist, ketanserin (10, 100 μM), produced dose-dependent neuroprotection against the ischemia-induced decrease. However, in normal non-ischemic solution these treatments did not significantly change the CA1 field potential. The protective action of Y-25130 was blocked by co-treatment with 2-methyl-5-HT. The magnitude of protection in the Y-25130-treated group (EC50, 1.8 μM) was about 20 times greater than that in the ketanserin-treated group (EC50, 33 μM). The present study demonstrated that stimulation of 5-HT3 receptors plays a detrimental role in the development of ischemic damage, whereas blockade of the 5-HT3 receptor plays a neuroprotective role in ischemic damage, suggesting a facilitatory role of 5-HT neurons in ischemia-induced neuronal deficits.

Original languageEnglish
Pages (from-to)51-56
Number of pages6
JournalEuropean Journal of Pharmacology
Volume224
Issue number1
DOIs
Publication statusPublished - 1992 Nov 24
Externally publishedYes

Fingerprint

Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Neuroprotective Agents
Ischemia
Serotonin 5-HT3 Receptor Agonists
Ketanserin
Serotonin 5-HT2 Receptor Antagonists
Hypoglycemia
Hippocampus
Serotonin
Neurons
azasetron

Keywords

  • (In vitro)
  • 5-HT (5-hydroxytryptamine, serotonin)
  • 5-HT receptors
  • CA1 field potential
  • Hippocampus
  • Hypoxia/hypoglycemia
  • Ischemia

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Neuroprotective effect of 5-HT3 receptor antagonist on ischemia-induced decrease in CA1 field potential in rat hippocampal slices. / Kagami-ishi, Yoshifumi; Shibata, Shigenobu; Watanabe, Shigenori.

In: European Journal of Pharmacology, Vol. 224, No. 1, 24.11.1992, p. 51-56.

Research output: Contribution to journalArticle

@article{c9b81c17ed8b42d5beda2672abdb1dca,
title = "Neuroprotective effect of 5-HT3 receptor antagonist on ischemia-induced decrease in CA1 field potential in rat hippocampal slices",
abstract = "The effect of 5-HT3 receptor agonists and antagonists on the hypoxia/hypoglycemia (ischemia)-induced decrease in CA1 field potential elicited by stimulation of Schaffer collaterals was investigated using rat hippocampal slices. Treatment with the 5-HT3 receptor agonist, 2-methyl-5-HT (1-10 μM), exaceebated the ischemia-induced decreased in CA1 field potential, whereas treatment with the 5-HT3 receptor antagonist. Y-25130 (0.1-100 μM), or the 5-HT2 receptor antagonist, ketanserin (10, 100 μM), produced dose-dependent neuroprotection against the ischemia-induced decrease. However, in normal non-ischemic solution these treatments did not significantly change the CA1 field potential. The protective action of Y-25130 was blocked by co-treatment with 2-methyl-5-HT. The magnitude of protection in the Y-25130-treated group (EC50, 1.8 μM) was about 20 times greater than that in the ketanserin-treated group (EC50, 33 μM). The present study demonstrated that stimulation of 5-HT3 receptors plays a detrimental role in the development of ischemic damage, whereas blockade of the 5-HT3 receptor plays a neuroprotective role in ischemic damage, suggesting a facilitatory role of 5-HT neurons in ischemia-induced neuronal deficits.",
keywords = "(In vitro), 5-HT (5-hydroxytryptamine, serotonin), 5-HT receptors, CA1 field potential, Hippocampus, Hypoxia/hypoglycemia, Ischemia",
author = "Yoshifumi Kagami-ishi and Shigenobu Shibata and Shigenori Watanabe",
year = "1992",
month = "11",
day = "24",
doi = "10.1016/0014-2999(92)94817-F",
language = "English",
volume = "224",
pages = "51--56",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Neuroprotective effect of 5-HT3 receptor antagonist on ischemia-induced decrease in CA1 field potential in rat hippocampal slices

AU - Kagami-ishi, Yoshifumi

AU - Shibata, Shigenobu

AU - Watanabe, Shigenori

PY - 1992/11/24

Y1 - 1992/11/24

N2 - The effect of 5-HT3 receptor agonists and antagonists on the hypoxia/hypoglycemia (ischemia)-induced decrease in CA1 field potential elicited by stimulation of Schaffer collaterals was investigated using rat hippocampal slices. Treatment with the 5-HT3 receptor agonist, 2-methyl-5-HT (1-10 μM), exaceebated the ischemia-induced decreased in CA1 field potential, whereas treatment with the 5-HT3 receptor antagonist. Y-25130 (0.1-100 μM), or the 5-HT2 receptor antagonist, ketanserin (10, 100 μM), produced dose-dependent neuroprotection against the ischemia-induced decrease. However, in normal non-ischemic solution these treatments did not significantly change the CA1 field potential. The protective action of Y-25130 was blocked by co-treatment with 2-methyl-5-HT. The magnitude of protection in the Y-25130-treated group (EC50, 1.8 μM) was about 20 times greater than that in the ketanserin-treated group (EC50, 33 μM). The present study demonstrated that stimulation of 5-HT3 receptors plays a detrimental role in the development of ischemic damage, whereas blockade of the 5-HT3 receptor plays a neuroprotective role in ischemic damage, suggesting a facilitatory role of 5-HT neurons in ischemia-induced neuronal deficits.

AB - The effect of 5-HT3 receptor agonists and antagonists on the hypoxia/hypoglycemia (ischemia)-induced decrease in CA1 field potential elicited by stimulation of Schaffer collaterals was investigated using rat hippocampal slices. Treatment with the 5-HT3 receptor agonist, 2-methyl-5-HT (1-10 μM), exaceebated the ischemia-induced decreased in CA1 field potential, whereas treatment with the 5-HT3 receptor antagonist. Y-25130 (0.1-100 μM), or the 5-HT2 receptor antagonist, ketanserin (10, 100 μM), produced dose-dependent neuroprotection against the ischemia-induced decrease. However, in normal non-ischemic solution these treatments did not significantly change the CA1 field potential. The protective action of Y-25130 was blocked by co-treatment with 2-methyl-5-HT. The magnitude of protection in the Y-25130-treated group (EC50, 1.8 μM) was about 20 times greater than that in the ketanserin-treated group (EC50, 33 μM). The present study demonstrated that stimulation of 5-HT3 receptors plays a detrimental role in the development of ischemic damage, whereas blockade of the 5-HT3 receptor plays a neuroprotective role in ischemic damage, suggesting a facilitatory role of 5-HT neurons in ischemia-induced neuronal deficits.

KW - (In vitro)

KW - 5-HT (5-hydroxytryptamine, serotonin)

KW - 5-HT receptors

KW - CA1 field potential

KW - Hippocampus

KW - Hypoxia/hypoglycemia

KW - Ischemia

UR - http://www.scopus.com/inward/record.url?scp=0026574860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026574860&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(92)94817-F

DO - 10.1016/0014-2999(92)94817-F

M3 - Article

C2 - 1451743

AN - SCOPUS:0026574860

VL - 224

SP - 51

EP - 56

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -